Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + SRS in Melanoma Brain/Spine Metastases
NCT02716948Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2016
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in melanoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Incidence of Serious Adverse Events at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02716948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716948.